Companies
Bristol Myers Squibb
Breyanzi (lisocabtagene maraleucel, CD19) had its monitoring and activity update approved in Canada in June 2026, and BMS co-develops Abecma (idecabtagene vicleucel, BCMA) with 2seventy bio for multiple myeloma.
- Country
- United States
- Ticker
- BMY
Commercial
BCMA CAR-T (Breyanzi/Abecma)
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $48.2 billion in 2025 | bms.com · contractpharma.com · sec.gov |
| Headcount | ~5,000 (cell therapy operations) to 34,100 (total company) employees | bms.com · contractpharma.com |
| Production site | Devens, Massachusetts (cell therapy) | news.bms.com · contractpharma.com · fiercepharma.com |
| Production site | Bothell, Washington; Summit, New Jersey; Warren, New Jersey (cell therapy) | news.bms.com · bms.com · contractpharma.com · fiercepharma.com |
| Production site | Leiden, Netherlands (cell therapy, in development/completed) | news.bms.com · bms.com · contractpharma.com · fiercepharma.com |
| Regulatory approval | Breyanzi monitoring/activity update approved in Canada June 2026; U.S. label updates for Breyanzi and Abecma June 2025 | investors.bms.com · news.bms.com · bms.com · hematologyadvisor.com |
| Capacity | Expanding through new sites (Devens, Leiden) and innovative manufacturing solutions medium confidence | news.bms.com · bms.com · contractpharma.com · fiercepharma.com |
Independent sources: bms.com · contractpharma.com · fiercepharma.com · hematologyadvisor.com · investors.bms.com · news.bms.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
| CAR-T cell therapy | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.